Herpes Zoster

Also known as: Shingles / Zoster [herpes zoster] / Zona / Herpes zoster NOS

DrugDrug NameDrug Description
DB00787AcyclovirA guanosine analog antiviral drug that acts as an antimetabolite. Aciclovir is used for the treatment of herpes simplex virus infections, varicella zoster (chickenpox) and herpes zoster (shingles). Aciclovir has also been investigated for the treatment of herpes labialis applied using an iontophoretic device. Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the site where the herpes virus is replicating. Iontophoresis uses electric current to enhance the delivery of drugs through the skin.
DB14016Ox bile extractNot Available
DB10318Varicella Zoster Vaccine (Live/Attenuated)Live attenuated zoster vaccine is available as two products: Zostavax for the prevention of shingles in immunocompetent people over the age of 50, and Varivax for the prevention of chickenpox in individuals 12 months of age and older. While the two vaccines contain the same immunological components and provide protection against the same virus, Zostavax contains a higher dose and is used in older adults to prevent the development of shingles and post-herpetic neuralgia. First approved in May 2006 by the Food and Drug Administration, Zostavax was the first vaccine available for the prevention of shingles. Since October 2017, however, it has been replaced as first line therapy by Shingrix ([DB13924]), a more effective and longer lasting vaccine[L1038]. Both Varivax and Zostavax are composed of a lyophilized preparation of live, attenuated Oka/Merck strain of varicella-zoster virus. Varicella Zoster Virus (VZV) is the virus that commonly causes Chickenpox (also known as Varicella) in childhood [L1040]. Following initial infection of VZV and resolution of Chickenpox as a child, VZV then lies dormant within the dorsal root ganglion of the central nervous sytem. Decades later, when the body's immune system weakens with age, VZV is able to reactivate and descend through the nerve cells to the surface of the skin where it causes a painful blistering rash, known as shingles (or Herpes Zoster). Risk factors for developing shingles include old age, with rates increasing substantially in person's over the age of 50, low immune function or immunosuppression, psychological stress, and diabetes. Person's living with HIV or cancer, those taking immunosuppressants, and transplant recipients are particularly at risk [L1037]. One of the most common complications associated with shingles is the development of Post-Herpetic Neuralgia (PHN), a persistant severe nerve pain that develops as a result of chronic pain from shingles lesions. PHN can last for days, months, or even years following resolution of shingles. Other complications also include bacterial infection, spread of the shingles rash to the eye (herpes zoster ophthalmicus) or ear, nerve palsies, or spread of VZV to non-immune persons via contact with varicella lesions. There are numerous advantages to using Shingrix over Zostavax. Clinical trials for Shingrix have shown greater than 90% efficacy in adults aged 50 and older, with 89% efficacy in preventing postherpetic neuralgia in patients 70 years and older and 91% efficacy in patients 50-70 years of age. This is a significant improvement over its predecessor, Zostavax, which reduces the risk of shingles by only 51% and the risk of post-herpetic neuralgia by 67% [A31349]. Efficacy of Zostavax also wanes over time, with protection against shingles and PHN lasting only around 5 years. Efficacy for prevention of shingles is highest in patients 60-69 years old and decreases with increasing age. Furthermore, because Shingrix is an inactivated vaccine it can also be used to prevent shingles and PHN in individuals with suppressed immune systems, who are already at increased risk of developing shingles, while Zostavax, a live attenuated vaccine, is contraindicated.
DB13924Varicella Zoster Vaccine (Recombinant)Recombinant zoster vaccine, manufactured as the product Shingrix by GlaxoSmithKline, is an adjuvanted non-live recombinant vaccine indicated for prevention of shingles. First approved in October 2017 by the Food and Drug Administration, Shingrix is the preferred vaccine for preventing varicella zoster infection in people aged 50 years and older, replacing Zostavax as first line therapy[L1038]. Herpes zoster, also known as shingles, is caused by a reactivation of Varicella Zoster Virus (VZV), the virus that commonly causes Chickenpox in childhood. Following initial infection of VZV and resolution of Chickenpox as a child, VZV then lies dormant within the dorsal root ganglion of the central nervous sytem. Decades later, when the body's immune system weakens with age, VZV is able to reactivate and descend through the nerve cells to the surface of the skin where it causes a painful blistering rash. Risk factors for developing shingles include old age, with rates increasing substantially in person's over the age of 50, low immune function or immunosuppression, psychological stress, and diabetes. Person's living with HIV or cancer, those taking immunosuppressants, and transplant recipients are particularly at risk [L1037]. One of the most common complications associated with shingles is the development of Post-Herpetic Neuralgia (PHN), a persistant severe nerve pain that develops as a result of chronic pain from shingles lesions. PHN can last for days, months, or even years following resolution of shingles. Other complications also include bacterial infection, spread of the shingles rash to the eye (herpes zoster ophthalmicus) or ear, nerve palsies, or spread of VZV to non-immune persons via contact with varicella lesions. There are numerous advantages to using Shingrix over Zostavax. Clinical trials for Shingrix have shown greater than 90% efficacy in adults aged 50 and older, with 89% efficacy in preventing postherpetic neuralgia in patients 70 years and older and 91% efficacy in patients 50-70 years of age [FDA Label]. This is a significant improvement over its predecessor, Zostavax, which reduces the risk of shingles by only 51% and the risk of post-herpetic neuralgia by 67% [A31349]. Efficacy of Zostavax also wanes over time, with protection against shingles and PHN lasting only around 5 years. Furthermore, because Shingrix is an inactivated vaccine it can also be used to prevent shingles and PHN in individuals with suppressed immune systems, who are already at increased risk of developing shingles, while Zostavax, a live attenuated vaccine, is contraindicated. The main immunological component of Shingrix vaccine is glycoprotein E (gE), a protein found on the surface of varicella zoster virus (VZV). Immune exposure to gE protein stimulates the development of anti-gE antibodies, and therefore adaptive immunity to VZV. Shingrix also contains an adjuvant system, AS01B, which is intended to enhance the immunological response to the vaccine leading to longer lasting and greater immunogenicity to the herpes zoster virus [L1036].
DrugDrug NamePhaseStatusCount
DB11701Amenamevir1Completed1
DB09153Sodium chloride1Recruiting1
DB10318Varicella Zoster Vaccine (Live/Attenuated)1Active Not Recruiting1
DB10318Varicella Zoster Vaccine (Live/Attenuated)1Completed2
DB09153Sodium chloride1 / 2Completed1
DB10318Varicella Zoster Vaccine (Live/Attenuated)1 / 2Withdrawn1
DB11701Amenamevir2Completed1
DB06774Capsaicin2Completed1
DB12338Carisbamate2Completed1
DB00514Dextromethorphan2Completed1
DB05214KD70402Completed1
DB00230Pregabalin2Terminated1
DB09153Sodium chloride2Completed1
DB11998Sorivudine2Unknown Status1
DB00577Valaciclovir2Completed3
DB00577Valaciclovir2Unknown Status1
DB06575Valomaciclovir2Completed1
DB10318Varicella Zoster Vaccine (Live/Attenuated)2Completed3
DB10318Varicella Zoster Vaccine (Live/Attenuated)2Recruiting1
DB00787Acyclovir3Completed1
DB11701Amenamevir3Completed1
DB00415Ampicillin3Completed1
DB05318Capsaicin3Completed2
DB10583Clostridium tetani toxoid antigen (formaldehyde inactivated)3Completed1
DB01151Desipramine3Completed1
DB00426Famciclovir3Completed2
DB10791Influenza A virus A/california/7/2009 x-179a (H1N1) antigen (formaldehyde inactivated)3Completed2
DB00333Methadone3Completed1
DB00295Morphine3Completed1
DB00540Nortriptyline3Completed1
DB10319Streptococcus pneumoniae type 1 capsular polysaccharide antigen3Completed1
DB00577Valaciclovir3Completed1
DB00577Valaciclovir3Terminated1
DB10318Varicella Zoster Vaccine (Live/Attenuated)3Completed9
DB13924Varicella Zoster Vaccine (Recombinant)3Completed1
DB06361rsPSMA Vaccine3Recruiting1
DB00787Acyclovir4Unknown Status1
DB00529Foscarnet4Unknown Status1
DB00996Gabapentin4Completed1
DB00230Pregabalin4Recruiting1
DB10318Varicella Zoster Vaccine (Live/Attenuated)4Completed3
DB10318Varicella Zoster Vaccine (Live/Attenuated)4Recruiting1
DB13924Varicella Zoster Vaccine (Recombinant)4Recruiting1
DB00426FamciclovirNot AvailableNot Yet Recruiting1
DB00996GabapentinNot AvailableCompleted1
DB00996GabapentinNot AvailableNot Yet Recruiting1
DB00497OxycodoneNot AvailableNot Yet Recruiting1
DB00577ValaciclovirNot AvailableCompleted4
DB10318Varicella Zoster Vaccine (Live/Attenuated)Not AvailableActive Not Recruiting1
DB10318Varicella Zoster Vaccine (Live/Attenuated)Not AvailableCompleted1